Anti-BCMA car antibodies, conjugates, and methods of use
Inventors
Friedman, Kevin • PERKINS, Molly Reed
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12545746-B2
Publication Date
2026-02-10
Expiration Date
Abstract
The invention provides improved methods for detecting anti-BCMA CAR expression on T cells. The invention generally provides antibodies and antigen binding fragments thereof, conjugates thereof, and methods of using the same to detect, determine, or measure CAR T cells and/or CAR expression on one or more T cells.
Core Innovation
The invention provides an antibody or antigen binding fragment that comprises a variable light chain sequence set forth in SEQ ID NO: 7 and a variable heavy chain sequence set forth in SEQ ID NO: 8. The antibody or antigen binding fragment binds anti-BCMA CAR-related epitopes defined by anti-BCMA CAR sequences set forth in SEQ ID NO: 9 and/or SEQ ID NO: 10.
The disclosure further provides antibody formats and related binding forms, including antigen binding fragments and an scFv format, as well as immunoglobulin constant domain options such as IgG1, IgG2, IgG3, and IgG4. It also includes detectable labeled conjugates in which the antibody or antigen binding fragment is conjugated with a detectable label from multiple classes described in the document, including fluorophores, haptens, enzymes, and radionuclides.
The invention enables detection, determination, measurement, and enumeration of anti-BCMA CAR expression on immune effector cells, notably T cells. It is described as being based on contacting the T cell with the antibody or antigen binding fragment, detecting formation of an antibody:anti-BCMA CAR complex, and measuring the amount of that complex.
Claims Coverage
The provided content includes one independent claim. The claim coverage centers on an antibody or antigen binding fragment defined by specific variable light and variable heavy chain sequences, with related features directed to anti-BCMA CAR epitope binding, alternative formats and constant domains, labeled conjugates, and a method for determining anti-BCMA CAR expression on T cells.
Variable light chain SEQ ID NO: 7 and variable heavy chain SEQ ID NO: 8
An antibody or antigen binding fragment thereof comprising a variable light chain sequence set forth in SEQ ID NO: 7 and a variable heavy chain sequence set forth in SEQ ID NO: 8.
Binding epitopes recognized by anti-BCMA CAR sequences SEQ ID NO: 9 and/or SEQ ID NO: 10
The antibody or antigen-binding fragment binds one or more epitopes recognized by an anti-BCMA CAR sequence defined by SEQ ID NO: 9 and/or SEQ ID NO: 10.
IgG constant domain selected from IgG1, IgG2, IgG3, or IgG4
An antibody or an antigen-binding fragment having an IgG1, IgG2, IgG3, or IgG4 constant domain.
Conjugate with detectable label selected from specified AlexaFluor dyes
A conjugate where the detectable label is selected from AlexaFluor dyes including AF350, AF405, AF488, AF500, AF514, AF532, AF546, AF555, AF568, AF594, AF610, AF633, AF635, AF647, AF680, AF700, AF710, AF750, AF790, and AF800.
Determining anti-BCMA CAR expression on a T cell by measuring antibody:anti-BCMA CAR complex
A method for determining the expression of an anti-BCMA CAR on a T cell by contacting the T cell with an antibody or antigen-binding fragment, detecting formation of an antibody:anti-BCMA CAR complex, and measuring the amount of that complex.
The claim coverage defines antibodies by specific variable light and heavy chain sequence identities, specifies binding to epitopes recognized by anti-BCMA CAR sequences SEQ ID NO: 9 and/or SEQ ID NO: 10, includes constant domain and labeled conjugate features, and provides a method concept for determining anti-BCMA CAR expression on T cells by detecting and measuring an antibody:anti-BCMA CAR complex.
Stated Advantages
Documented Applications
No documented applications found
Interested in licensing this patent?